TERMINATION AND PHASE OUT OF OUTSTANDING INVESTIGATOR GRANT AWARDS NIH GUIDE, Volume 21, Number 24, July 3, 1992 P.T. 34 Keywords: Grants Administration/Policy+ National Cancer Institute The National Cancer Institute (NCI), with the concurrence of the National Cancer Advisory Board, announces plans for the orderly phase out and termination of its Outstanding Investigator Grant (OIG) program. All non-competing commitments for future year support made to current grantees will continue to be honored as indicated on the current Notice of Award. This announcement makes permanent the moratorium on new (Type 1) applications announced previously (NIH Guide Vol. 21, Number 14, April 10, 1992). Any Type 1 OIG awards made in Fiscal 1993, based on previously reviewed applications, will be for a 7-year project period and will be non-renewable as an OIG as a condition of award. Currently funded OIG investigators who already have submitted either original or amended competing continuation applications (Type 2) for the June 1, 1992 receipt date for consideration at the January 1993 National Cancer Advisory Board meeting will be considered to have submitted a final competing application. Competitive but unfunded Type 2 applications from that Board round will be kept in an eligible status for an additional fiscal year. Therefore, such applicants will not be permitted to submit an amended competing continuation application for the subsequent receipt date. Where necessary to allow an orderly transition to other support, OIG grantees may request administrative extensions without additional funds for up to one year. For all other current OIG awardees, a final round of Type 2 competing continuation applications will be accepted for the June 1, 1993 receipt date under the conditions specified below. This will be the last competing receipt date for the program prior to its termination. 1. Only investigators whose current OIG awards will be in the -05 or -06 year in Fiscal 1993, and who have not submitted a competing application for the June 1992 receipt date, may submit a final, non-renewable competing continuation application on June 1, 1993, requesting up to seven years of additional support starting on the next closest anniversary date of the current award. The first competing year proposed budget may not be increased more than 15 percent over the last non-competing (-07) year actual award. Applications requesting a budgetary increase of greater than 15 percent above the -07 year level will be accepted only with the prior approval of the NCI Executive Committee. Periods of time less than seven years may be requested for this class of application. 2. Any other investigator holding a non-competing Type 5 NCI OIG award may, regardless of current non-competing years remaining, at his/her own option, submit for the June 1, 1993 receipt date a final, non-renewable competing continuation application requesting five additional years of support, with the new budget period to commence from the next closest immediate anniversary date of the current grant period following selection for funding. This submission will not place at risk the current award, should the competing continuation application fail to be funded. The first competing year budget may not request more than a 10 percent increment over the comparable recommended budget level in the current award. Future year requests may not exceed current NIH award increment policies. Although funds for these awards are provided for in the projected plans of the NCI, given the uncertainties of budgets for future fiscal years, it would be prudent for all applicants to submit individual research project grant applications (e.g., R01 or P01) at the appropriate time as alternative potential means of support should the competing continuation OIG application not be funded. Current OIG awardees are strongly encouraged to contact the NCI program official identified on the Notice of Award to discuss future options for the transition from support under the OIG to support under other investigator-initiated grant mechanisms. INQUIRIES For additional information or for questions concerning this notice, contact: Mrs. Barbara S. Bynum Director, Division of Extramural Activities National Cancer Institute Building 31, Room 10A03 Bethesda, MD 20892 Telephone: (301) 496-5147 FAX: (301) 402-0062 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |